Stocktoria
Lupin Limited LUPIN.NS
Lupin Limited (LUPIN.NS) earns a Piotroski F-score of 8/9 (strong financial health). It pays a dividend yielding 0.50% (safety: safe). FY2026 revenue was ₹274.9B at a 19.4% net margin.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women's health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company has a strategic collaboration with TB Alliance for the development and commercialization of the investigational drug Telacebec for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
How it ranks in Healthcare · percentile among 73 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
FAQ
Is LUPIN.NS financially healthy?
Lupin Limited's Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak).
Does LUPIN.NS pay a dividend, and is it safe?
Yes. Lupin Limited pays a dividend yielding about 0.50% with a 10.3% payout ratio, rated “safe” for safety.
How profitable is LUPIN.NS?
In FY2026, Lupin Limited had a net margin of 19.4% and a return on equity of 23.8%.
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.